Get 40% Off
☕ Buy the dip? After losing 17%, Starbucks sees an estimated 20% upside. See the top Undervalued stocks!Unlock list

Celanese Inks Deal With Linde To Buy Syngas Production Unit

Published 01/16/2019, 08:14 PM
Updated 07/09/2023, 06:31 AM

Celanese Corporation (NYSE:CE) has entered into a definitive agreement to purchase a synthesis gas production unit of 365 kilo tons per annum from Linde PLC. The unit is located at the Celanese Clear Lake acetyl intermediates manufacturing facility in Pasadena, TX.

Syngas is a combination of carbon dioxide, carbon monoxide and hydrogen. It can be produced from sources like coal, biomass, natural gas, or any hydrocarbon feedstock, with the reaction of oxygen or steam. Moreover, syngas is an important resource for the production of ammonia, acetic acid, methanol, synthetic hydrocarbon fuels and hydrogen.

With this acquisition, Celanese will now have the capacity to produce a key raw material for the world’s largest acetyl intermediates production facility. Linde is the primary supplier of carbon monoxide to the Clear Lake facility and the acquisition of syngas production unit is likely to open up productivity and growth opportunities for Celanese.

Celanese and Linde are expected to complete the deal upon meeting customary closing conditions and receiving regulatory approvals. However, the financial details of the deal have been kept under wraps.

In the past six months, Celanese has underperformed the industry it belongs to. The stock has lost around 14.7% compared with the industry’s fall of 8.9%.



Celanese, in October 2018, raised its adjusted earnings per share guidance for 2018 to $10.90-$11.10, owing to strength in Engineered Materials (EM) and Acetyl Chain units. The company expects momentum in Acetyl Chain and EM to continue. The EM segment is expected to maintain the pace of earnings growth with traction from new projects and bolt-on acquisitions.

Celanese is taking appropriate pricing actions amid a volatile pricing environment for raw materials. The company’s strategic measures including operational cost savings through productivity actions and price hike initiatives are likely to provide an impetus to earnings.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Celanese Corporation Price and Consensus

Zacks Rank & Stocks to Consider

Celanese currently carries a Zacks Rank #4 (Sell).

A few better-ranked stocks in the basic materials space are Ingevity Corporation (NYSE:NGVT) , Israel Chemicals Ltd. (NYSE:ICL) and Cameco Corporation (NYSE:CCJ) .

Ingevity’s shares have gained 19% in the past year. The company has an expected earnings growth rate of 21.5% for 2019 and it currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Israel Chemicals has an expected earnings growth rate of 2.7% for 2019 and a Zacks Rank #2 (Buy). The stock has rallied 30.4% in a year.

Cameco has an expected earnings growth rate of 20% for 2019 and a Zacks Rank #2. Its shares have gained 28.5% in a year.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>



Celanese Corporation (CE): Get Free Report

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
Ingevity Corporation (NGVT): Free Stock Analysis Report

Israel Chemicals Shs (ICL): Free Stock Analysis Report

Cameco Corporation (CCJ): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.